Skip to Content

Generic Secuado Availability

Last updated on Sep 8, 2021.

Secuado is a brand name of asenapine, approved by the FDA in the following formulation(s):

SECUADO (asenapine - system;transdermal)

  • Manufacturer: HISAMITSU
    Approval date: October 11, 2019
    Strength(s): 3.8MG/24HR [RLD], 5.7MG/24HR [RLD], 7.6MG/24HR [RLD]

Has a generic version of Secuado been approved?

No. There is currently no therapeutically equivalent version of Secuado available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Secuado. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patch
    Patent 10,022,445
    Issued: July 17, 2018
    Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.

    In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

    Patent expiration dates:

    • July 25, 2033
      ✓ 
      Drug product
  • Patent 10,583,121

    Patent expiration dates:

    • July 25, 2033
      ✓ 
      Patent use: METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
      ✓ 
      Drug product
  • Patent 10,814,002

    Patent expiration dates:

    • July 25, 2033
      ✓ 
      Patent use: METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
      ✓ 
      Drug product
  • Patch
    Patent 9,687,474
    Issued: June 27, 2017
    Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.

    In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.

    Patent expiration dates:

    • July 25, 2033
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 11, 2022 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.